TAVR for a leaky aortic valve
Part of Heart & circulation clinical trials.
This trial is testing a less invasive procedure (TAVR) to fix a leaky aortic valve without open-heart surgery. It's for people with severe aortic regurgitation who are either having symptoms or showing signs of heart strain, and who are not good candidates for traditional surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have severe aortic regurgitation (a leaky heart valve) confirmed by ultrasound
- You have symptoms (like shortness of breath or chest pain) or tests show your heart is struggling
- Your heart team decides TAVR (a less invasive valve replacement) is safe for you, for example if surgery is too risky
- You do not have an active infection in your heart or a serious body-wide infection
- You do not have a large aneurysm or other aortic problems that need open surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new, less invasive heart valve system (TaurusTrio) for people with severe aortic regurgitation (a leaky aortic valve) who cannot have open-heart surgery. It aims to see if the valve is safe and works well to improve symptoms.
This trial tests a less invasive heart valve replacement (TAVR) for people with a leaky aortic valve (aortic regurgitation). It uses ultrasound guidance to place the new valve, which may offer a treatment option for those who cannot have open-heart surgery.
This trial tests whether a 3D computer simulation can help guide a less invasive procedure (TAVR) to replace a leaky aortic valve. It may be an option for people with severe aortic regurgitation who are at least 65 years old.
This trial tests whether a new valve replacement procedure (TAVR) is safe and effective for people with severe aortic regurgitation, a leaky heart valve. It is designed for patients who are not good candidates for open-heart surgery because of other health conditions.
This trial compares a new less-invasive valve replacement (Trilogy TAVR) with standard open-heart surgery for people with significant aortic regurgitation. It aims to see which treatment works better for patients who are eligible for both procedures.
This trial studies whether a new through-the-blood-vessel heart valve (TAVR) is safe and works well for people with severe aortic stenosis who are too risky for traditional surgery. If you qualify, you would be closely followed to check your symptoms and valve function over time.
Hear when a new Aortic Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.